share_log

Barclays Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $67

Barclays Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $67

巴克莱对CRISPR Therapeutics保持同等权重,将目标股价下调至67美元
Benzinga ·  05/09 10:50

Barclays analyst Gena Wang maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and lowers the price target from $80 to $67.

巴克莱分析师王杰纳维持CRISPR Therapeutics(纳斯达克股票代码:CRSP)的权重相等,并将目标股价从80美元下调至67美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发